Info

12. Ikehara S. The prospects for BMT-from mouse to hu- 26. man. In: Ikehara S, Takaku F, Good RA, eds., Bone

Marrow Transplantation. Basic and Clinical Studies. Tokyo-Singapore: Springer-Verlag 1996;302—331. Drakos P, Nagler A, Or R. Case of Crohn's disease in bone marrow transplantation (letter to the editor) Am J Hematol 1993;43:157-157. Nelson JL, Torrez R, Miu Louie F, Choe OS, Strob R, Sullivan KM. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol 1997;24(suppl 48): 23-29.

Sullivan, KM, Furst, DE. The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. J Rheumatology 1997;24:1^1. Van Bekkum DW, Marmont AM, Tyndall A, Vriesendorp FJ, Apatoff BJ. Severe autoimmune disease: a new target for bone marrow transplantation. Stem Cells 1996;14:460-472. Marmont AM. Immune ablation followed by allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune disease? Stem Cells 1994;12:125-135.

McAllister LD, Beatty PG, Rose J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant 1997;19:395-397.

Fassas A, Anagnastopoulos A, Kazis A. Peripheral blood stem-cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997;20:631-638. Marmont AM: Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases. J Rheumatol 1997;24(suppl 48): 13—1.

Marmont, A.M. Stem cell therapy for severe autoimmune disease: The present situation. J Hellenic Soc Haematol 1998;1:1-30.

Burt RK, Burns W, Hess A: Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant 1995;16:1-6.

Zan-Bar I, Slavin S, Strober S. Induction and mechanism of tolerance to bovine serum albumin after total lymphoid irradiation (TLI). J Immunol 1978;121:1400-1404.

Zan-Bar I, Barzilay M, Moscovitch M, Slavin S. Regulation of the immune response in experimental models of autoimmune disorders: resistance of (NZBxNZW)Fl mice to tolerance induction in vivo. Clin Exp Immunol 1983;51:558-564. Kieselow P, Bluethmann H, StaerzUD, Steinmetz M, Von Boehmer H. Tolerance in T cell receptor transgenic mice involves deletion of nonmature thymocytes. Nature 1988;333:742-746. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik Y, Or R. Allogeneic cell therapy for relapsed leukemia following bone marrow transplan- 38. tation with donor peripheral blood lymphocytes. Exp Hematol 1995;23:1553-1562.

27. Slavin S, Naparstek E, Nagler A, Ackerstein A, 39. Samuel S, Kapelushnik J, Brautbar C, Or R. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 1996;87:2195-2204. 40.

28. Aker M, Kapelushnik J, Pugatsch T, Naparstek E, Nagler A, Ben-Naria S, Yehuda O, Amar A, Slavin S, Or R. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic BMT 41. for beta thalassemia major. J Ped Hematol/Oncol 1998;20:145-148.

29. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, 42. Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Ben-Tal O, Eldor A, Or R. Non-myeloablative stem-cell transplantation and cell therapy as an alternative to conventional bone marrow 43. transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998;91:756-763.

30. Naparstek E, Nagler A, Or R, Slavin S. Allogeneic 44. cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies. Clin Transplant 1996;281-290.

31. Reisner Y, Martelli MF. Bone marrow transplanta- 45. tion across HLA barriers by increasing the number of transplanted cells. Immunol Today 1995; 16:437.

32. Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T cell- depleted bone marrow overcomes MHC barriers in sublethally irradiated 46. mice. Natl Med 1995; 1:1268.

33. Rappaport J, Mihm M, Reinherz E, Lopansri S, Park-man R. Acute graft versus host disease in recipients of bone marrow transplants from identical twin donors. 47. Lancet. 1979;2:717-720.

34. Glazier A, Tutschka PJ, Farmer ER, Santos GW. Graft versus host disease in Cyclosporine A treated rats 48. after syngeneic and autologous bone marrow reconstitution. J Exp Med 1983;158:1.

35. Beschorner WE, Shinn CA, Fischer AC, Santos GW and Hess AD. Cyclosporine-induced pseudo-graft-vs-

host disease in the early post-cyclosporine period. 49. Transplant 1989;46(suppl): 112S-117S.

36. Cheney RT, Sprent J. Capacity of CSA to induce autologous GVHD and impair intrathymic T

cell differentiation. T Proceedings 1985; 18( 1 ):528- 50. 530.

37. Chow LH, Mosbach-Ozmen Laurence, Ryffel B, Borel JF. Syngeneic GVHD induced by CSA: a reappraisal. Transplantation 1988;46:1075-1125.

Jones RJ, Vogelsang GB, Hess AD. Induction of GVHD after autologous BMT. Lancet 1989; 1:754757.

Rizzoli V, Carella AM. Autologous marrow transplantation in ALL: Control of residual disease by mas-fosfamide and induction of syngeneic GVHD with cyclosporin. Bone Marrow Transplant 1990;6(suppl 1 ):76—78.

Yeager AM, Vogelsang GB, JMS RJ. Induction of cutaneous GVHD by administration of CSA in 8 pts undergoing autolgous BMT for AML. Blood. 1992;79:3031-3035.

George AJT and Stevenson FK. Prospects for the treatment of B cell tumours using idiotypic vaccination. Int Rev Immunol 1989;4:271-310. Rappaport J, Mihm M, Reinherz E, Lopansri S, Park-man R. Acute graft versus host disease in recipients of bone marrow transplants from identical twin donors. Lancet 1979;2:717-720.

Mehta S, Vourka-Karussis U, Mehta J, Shimon S, Weiss L. Failure of cyclosporine to induce graft-vs-host disease or graft-vs-leukemia after syngeneic BMT in mice. Leukemia Res 1996:20;941-946. Bonini C, Ferrari G, Verzeletti S, Srvida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia. Science 1997;276:1719-1724. Soderberg C, Larsson S, Rozell BL, Sumitran-Karuppan S, Ljungman P, Moller E. Cyto-megalovirus-induced CD13-specific autoimmunity— a possible cause of chronic graft-vs-host disease. Transplantation 1996;61:600-609. Soderberg C, Sumitran-Karuppan S, Ljungman P, Moller E. CD 13—specific autoimmunity in cytomegalovirus-infected immunocompromised patients. Transplantation 1996;61(4):594-600. Parkman R. Is chronic graft-versus-host disease an autoimmune disease? Curr Opin Immunol 1993;5(5):800-803.

Hiroki A, Nakamura S, Shinohara M, Gondo H, Ohyama Y, Hayashi S, Harada Mm Niho Y, Oka M. A comparison of glandular involvememt between chronic graft-versus-host disease and Sjogren's syndrome. Int J Oral Maxillofac Surg 1996;25:298-307. Holmes JA, Livesey SJ, Bedwell AE, Amos N, Whittaker JA. Autoantibody analysis in chronic graft-versus-host disease. Bone Marrow Transplant 1989;4:529-531.

Mencucci R, Rossi-Ferrini C, Bosi A, Volpe R, Guidi S, Slavi G. Ophtalmological aspects in allogeneic bone marrow transplantation: Sjögren-like syndrome in graft-vs-host disease. Eur J Ophtalmol 1997;7:13-18.

51. Lee S J, Churchill WH, Konugres A, Gilliland DG, Antin JH. Idiopathic thrombocytopenic purpura following allogeneic bone marrow transplantation— treatment with anti-D immunoglobulin. Bone Marrow Transplant 1997;19:173-174.

52. Sivakumaran M, Hutchinson RM, Pringle H, Graham S, Primrose L, Wood JK, Lauder I. Thrombocytopenia following autologous bone marrow transplantation: evidence for autoimmune aetiology and B cell clonal involvement. Bone Marrow Transplant 1995; 15:531— 536.

53. Klumpp TR. Antibody-mediated neutropenia following bone marrow transplantation. Int J Clin Lab Res 1993;23:4-7.

54. Bashey A, Owen I, Lucas GF, Amphlett NW, Jones MM, Lawal A, McMullin MF, Mahendra P, Tyfield LA, Hows JM. Late onset immune pancytopenia following bone marrow transplantation. Br J Haematol 1991;78:268-274.

55. Klumpp TR, Caligiuri MA, Rabinowe SN, Soiffer RJ, Murray C, Ritz J, Caligiuri MA. Autoimmune pancytopenia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1990;6:445-147.

56. Latal-Hajnal B, Lips U, Friedrich W, Zachmann M, Berthet F. Addison disease 10 years after bone marrow transplantation for Wiskott-Aldrich syndrome. Eur J Pediatr 1995;154:729-731.

57. Al-Fiar FZ, Colwill R, Lipton JH, Fyles G, Spaner D, Messner H. Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants. Bone Marrow Transplant 1997;19:1019-1022.

58. Wyatt DT, Lum LG, Casper J, Hunter J, Camitta B. Autoimmune thyroiditis after bone marrow transplantation. Bone Marrow Transplant 1990;5(5):357-361.

59. Thomson JA, Wilson RM, Franklin IM. Transmission of thyrotoxicosis of autoimmune type by sibling allogeneic bone marrow transplantation. Eur J Endocrinol 1995;133:564-566.

60. Kishimoto Y, Yamamoto Y, Ito T, Matsumoto N, Ichiyoshi H, Katsurada T, Date M, Ohga S, Kitajima H, Ikehara S, Fukuhara S. Transfer of autoimmune thyroiditis and resolution of palmoplantar pustular psoriasis following allogeneic bone marrow transplantation. Bone Marrow Transplant I997;19:1041-1043.

61. Lampeter EF, Homberg M, Quabeck K, Schaefer UW, Wernet P, Bertrams J, Grosse-Wilde H, Gries FA, Kolb H. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993;341 (8855): 12431244.

62. Vialettes B, Maraninchi D. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993;342:174.

63. Lampeter EF, McCann SR, Kolb H. Transfer of diabetes type 1 by bone marrow transplantation. Lancet 1997;351:568-569.

64. Bensussan A, David V, Vilmer E, Leca G, Boumsell L. Immunodeficiency after bone marrow transplantation can be associated with autoreactive T-cell receptor gamma delta-bearing lymphocytes. Immunol Rev 1990;116:5-13.

65. Sohngen D, Heyll A, Meckenstock G, Aul C, Wolf HH, Schneider W, Specker C, Withold W. Antiphos-pholipid syndrome complicating chronic graft-versus-host disease after allogeneic bone marrow transplantation. Am J Hematol 1994;47:143-144.

66. Tamura T, Kanamori H, Yamazaki E, Ohtsuka M, Hataoka K, Maeda K, Okamoto R, Tanabe J, Fujita H, Hashimoto Y. Cold agglutinin disease following bone marrow transplantation. Bone Marrow Transplant 1994;13:321-323.

67. Shimoda K, Gondo H, Harada M, Sano T, Nakamura M, Otsuka T, Okamura S, Niho Y. Myasthenia gravis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994;14:155-156.

68. Melms-A, Faul C, Sommer N, Wietholter H, Muller CA, Ehninger G. Myasthenia gravis after BMT: identification of patients at risk? Bone Marrow Transplant 1992;9:78-79.

69. Grau JM, Casademont J, Monforte R, Marin P, Gra-nena A, Rozman C, Urbano Markez A. Myasthenia gravis after allogeneic bone marrow transplantation: report of a new case of pathogenetic considerations. Bone Marrow Transplant 1990;5:435-437.

70. Eliashiv S, Brenner T, Abramsky O, Shahin R, Agai E, Naparstek E, Steiner I. Acute inflammatory demyeli-nating polyneuropathy following bone marrow transplantation. Bone Marrow Transplant 1991 ;8:315-317.

71. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75(3):555-562.

72. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989;320:828-834.

73. Stockschlaeder M, Storb R, Pepe M, et al. A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. Brit J Haemat 1992;80:49-54.

74. Bacigalupo A, van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cy-closporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991;77:1423-1428.

75. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik Y, Or R: Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995;23:1553-1562.

76. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 1996;87:2195-2204.

77. Slavin S, Fuks Z, Kaplan HS, Strober S. Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation. J Exp Med 1978;147:963-972.

78. Weiss L, Reich S, Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy. Cancer Invest 1992;10:19-26.

79. Johnson BD, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 1993; 11:329-336.

80. Naparstek E, Nagler A, Or R, Slavin S. Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies. Clin Transplant 1996;281-290.

81. Bonini C, Ferrari G, Verzeletti S, Srvida P, Zappone

E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia. Science 1997;276:1719-1724.

82. Kolb HJ, Mittermueller J, Clemm CH, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465.

83. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433.

84. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Ben-Tal O, Eldor A, Or R. Non-myeloablative stem-cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998;91(3):756-763.

85. Moscovitch M, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZBxNZW) F1 hybrids with spontaneous lymphosarcoma. J Immunol 1984;132:997-1000.

86. Morecki S, Yacovlev E, Diab A, Slavin S. Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res 1998 (in press).

87. Or R, Ackerstein A, Nagler A, Kapelushnik J, Naparstek E, Samuel S, Amar A, Brautbar C, Slavin. Allogeneic cell mediated immunotherapy for breast cancer after autologous stem-cell transplantation: A clinical pilot study. Cytokines, Cell Mol Ther 1998;4:1-6.

© 2000 Elsevier Science B. V. All rights reserved. Cancer and Autoimmunity Y. Shoenfeld and M. E. Gershwin, editors

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment